Filtered By:
Condition: Low Testosterone
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 106 results found since Jan 2013.
Endocrine Manifestations and New Developments in Mitochondrial Disease
Endocr Rev. 2022 May 12;43(3):583-609. doi: 10.1210/endrev/bnab036.ABSTRACTMitochondrial diseases are a group of common inherited diseases causing disruption of oxidative phosphorylation. Some patients with mitochondrial disease have endocrine manifestations, with diabetes mellitus being predominant but also include hypogonadism, hypoadrenalism, and hypoparathyroidism. There have been major developments in mitochondrial disease over the past decade that have major implications for all patients. The collection of large cohorts of patients has better defined the phenotype of mitochondrial diseases and the majority of patient...
Source: Endocrine Reviews - May 13, 2022 Category: Endocrinology Authors: Yi Shiau Ng Albert Zishen Lim Grigorios Panagiotou Doug M Turnbull Mark Walker Source Type: research
Severe Hemophilia A and Moyamoya Syndrome in a 19-Year-Old Boy Caused by Xq28 Microdeletion
In conclusion, diagnosis of MMD should be considered in any male, young patient with symptoms of ischemic stroke with no obvious explanation, and especially in patients with known hemophilia, since a relationship between the two conditions has been documented.Case Rep Neurol 2022;14:261 –267
Source: Case Reports in Neurology - May 30, 2022 Category: Neurology Source Type: research
Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research
ConclusionsCardiovascular outcomes were not worse in hypogonadism patients with TRT versus PDE5i; however, a potential association with AMI was found in patients with prior CVD receiving TRT versus PDE5i. Findings pointed to a pseudo-protective effect of triptans versus untreated migraine patients or those potentially older and less healthy patients exposed to prescription NSAIDs or opiates. Triptan users should not be compared with those using other anti-migraine prescriptions when evaluating cardiovascular outcomes in migraine patients. Presence of high cardiovascular risks may contribute to channeling bias —healthier ...
Source: Pharmaceutical Medicine - July 4, 2022 Category: Drugs & Pharmacology Source Type: research
Relationships between endogenous and exogenous testosterone and cardiovascular disease in men
Rev Endocr Metab Disord. 2022 Oct 11. doi: 10.1007/s11154-022-09752-7. Online ahead of print.ABSTRACTIn this narrative review, we discuss the evidence about the controversy about the cardiovascular effects of endogenous and exogenous testosterone in men. Prospective cohort studies with follow-up of ~5-15 years generally indicate no association or a possible inverse relationship between serum endogenous testosterone concentrations and composite major cardiovascular events, cardiovascular deaths and overall mortality. Pharmacoepidemiological studies of large databases generally show no association between testosterone therap...
Source: ENDOCR REV - October 11, 2022 Category: Endocrinology Authors: Arthi Thirumalai Bradley D Anawalt Source Type: research
Recognizing the True Value of Testosterone Therapy in Health Care
Androg Clin Res Ther. 2022 Dec 28;3(1):217-223. doi: 10.1089/andro.2022.0021. eCollection 2022.ABSTRACTThere has been little recognition within the medical community of the health impact of testosterone (T) deficiency (TD), also known as hypogonadism, and the substantial benefits of testosterone therapy (TTh) on health and quality of life despite high-level clinical evidence. In a roundtable symposium, investigators summarized the contemporary evidence in several key clinical areas. TD negatively impacts human health and quality of life and is associated with increased mortality. Several studies have demonstrated that TTh ...
Source: Clinical Prostate Cancer - January 16, 2023 Category: Cancer & Oncology Authors: Abraham Morgentaler Abdulmaged Traish Rajat S Barua Paresh Dandona Sandeep Dhindsa Mohit Khera Farid Saad Source Type: research
Research provides reassurance about the safety of testosterone treatment
Treatment with testosterone (the primary male sex hormone) does not increase the risk of heart attack, stroke or other diseases of the heart and blood vessels (cardiovascular disease), research found. The treatment was safe when given for less than a year to men with low levels of testosterone ( 2 External 0 0 0 hypogonadism false https://www.nhs.uk/conditions/male-menopause/#:~:text=Hypogonadism%20is%20sometimes%20present%20from,the%20%22male%20menopause%22%20symptoms. false false%>). Longer term follow up is ongoing.
Men with hypogonadism can experience loss of muscle mass, sexual problems, and reduced quality of life....
Source: Current Awareness Service for Health (CASH) - February 7, 2023 Category: Consumer Health News Source Type: news
Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment
AbstractPurpose of ReviewTesticular cancer (TC) is the leading cancer in men between 18 and 39 years of age. Current treatment involves tumor resection followed by surveillance and/or one or more lines of cisplatin-based chemotherapy (CBCT) and/or bone marrow transplant (BMT). Ten years after treatment, CBCT has been associated with significant atherosclerotic cardiovascular disease (CVD) i ncluding myocardial infarction (MI), stroke, and heightened rates of hypertension, dyslipidemia, diabetes mellitus, and metabolic syndrome (MetS). Additionally, low testosterone levels and hypogonadism contribute to MetS and may furth...
Source: Current Oncology Reports - March 3, 2023 Category: Cancer & Oncology Source Type: research
